DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $36,189,000 | +26.0% | 134,851 | +5.7% | 1.34% | +12.8% |
| Q1 2021 | $28,725,000 | -1.6% | 127,621 | -2.9% | 1.19% | -5.8% |
| Q4 2020 | $29,189,000 | +6.0% | 131,397 | +2.8% | 1.26% | -6.6% |
| Q3 2020 | $27,536,000 | +25.2% | 127,879 | +2.8% | 1.35% | +11.8% |
| Q2 2020 | $21,987,000 | +3.0% | 124,342 | -19.4% | 1.21% | -13.6% |
| Q1 2020 | $21,352,000 | -7.6% | 154,266 | +2.4% | 1.40% | +15.5% |
| Q4 2019 | $23,118,000 | +8.7% | 150,624 | +2.3% | 1.21% | 0.0% |
| Q3 2019 | $21,265,000 | +3.7% | 147,237 | +2.6% | 1.21% | +1.4% |
| Q2 2019 | $20,514,000 | +9.1% | 143,536 | +0.8% | 1.20% | +5.1% |
| Q1 2019 | $18,795,000 | +32.8% | 142,366 | +3.7% | 1.14% | +11.3% |
| Q4 2018 | $14,157,000 | -2.3% | 137,286 | +3.0% | 1.02% | +15.7% |
| Q3 2018 | $14,485,000 | -42.9% | 133,304 | -48.3% | 0.88% | +6.0% |
| Q2 2018 | $25,370,000 | +103.4% | 258,086 | +102.6% | 0.83% | +0.5% |
| Q1 2018 | $12,475,000 | +6.7% | 127,409 | +1.2% | 0.83% | +3.5% |
| Q4 2017 | $11,688,000 | +1.7% | 125,918 | -6.0% | 0.80% | -5.8% |
| Q3 2017 | $11,493,000 | -2.7% | 133,988 | -4.3% | 0.85% | -7.6% |
| Q2 2017 | $11,813,000 | -1.0% | 139,983 | +0.3% | 0.92% | -4.6% |
| Q1 2017 | $11,937,000 | +11.0% | 139,566 | +1.0% | 0.96% | +3.4% |
| Q4 2016 | $10,757,000 | -0.3% | 138,199 | +0.4% | 0.93% | -1.7% |
| Q3 2016 | $10,794,000 | -23.2% | 137,698 | -1.0% | 0.95% | -26.0% |
| Q2 2016 | $14,053,000 | +8.5% | 139,142 | +1.9% | 1.28% | +5.2% |
| Q1 2016 | $12,956,000 | +6.8% | 136,581 | +4.5% | 1.22% | +2.2% |
| Q4 2015 | $12,135,000 | +11.4% | 130,655 | +2.2% | 1.19% | +5.3% |
| Q3 2015 | $10,895,000 | -0.3% | 127,864 | +0.1% | 1.13% | +6.2% |
| Q2 2015 | $10,933,000 | +1.2% | 127,734 | +0.4% | 1.07% | +0.6% |
| Q1 2015 | $10,801,000 | +34.6% | 127,225 | +35.9% | 1.06% | +35.3% |
| Q4 2014 | $8,025,000 | +13.7% | 93,625 | +0.7% | 0.78% | +12.3% |
| Q3 2014 | $7,061,000 | -4.1% | 92,933 | -0.7% | 0.70% | -4.8% |
| Q2 2014 | $7,366,000 | +6.5% | 93,558 | +1.4% | 0.73% | +2.9% |
| Q1 2014 | $6,919,000 | +57.7% | 92,251 | +62.3% | 0.71% | +54.7% |
| Q4 2013 | $4,388,000 | – | 56,844 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |